Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
4.920
+0.070 (1.44%)
At close: Dec 18, 2025, 4:00 PM EST
4.920
0.00 (0.00%)
After-hours: Dec 18, 2025, 7:53 PM EST
Abeona Therapeutics Revenue
Revenue (ttm)
$400.00K
Revenue Growth
n/a
P/S Ratio
666.55
Revenue / Employee
$2,941
Employees
136
Market Cap
266.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 3.50M | 2.09M | 147.52% |
| Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
| Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
| Dec 31, 2020 | 10.00M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 3.00M | 2.16M | 258.18% |
| Dec 31, 2017 | 837.00K | -52.00K | -5.85% |
| Dec 31, 2016 | 889.00K | -151.00K | -14.52% |
| Dec 31, 2015 | 1.04M | 115.00K | 12.43% |
| Dec 31, 2014 | 925.00K | -1.12M | -54.70% |
| Dec 31, 2013 | 2.04M | -2.36M | -53.63% |
| Dec 31, 2012 | 4.40M | 2.57M | 139.48% |
| Dec 31, 2011 | 1.84M | 1.36M | 282.33% |
| Dec 31, 2010 | 481.00K | 129.00K | 36.65% |
| Dec 31, 2009 | 352.00K | 61.00K | 20.96% |
| Dec 31, 2008 | 291.00K | 234.00K | 410.53% |
| Dec 31, 2007 | 57.00K | - | - |
| Dec 31, 2005 | 57.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABEO News
- 3 days ago - Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer - GlobeNewsWire
- 7 days ago - Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas - GlobeNewsWire
- 10 days ago - Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy - GlobeNewsWire
- 17 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead - Seeking Alpha
- 5 weeks ago - Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 5 weeks ago - Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation - GlobeNewsWire